loading...| Preferred Name |
Gadodiamide |
| ID |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C65795 |
| CAS_Registry |
131410-48-5 |
| CHEBI_ID |
CHEBI:37333 |
| Chemical_Formula |
C16H26GdN5O8 |
| code |
C65795 |
| Concept_In_Subset |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116977 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C63923 |
| Contributing_Source |
CTRP FDA |
| DEFINITION |
A paramagnetic gadolinium-based contrast agent (GBCA), with imaging activity upon magnetic resonance imaging (MRI). When placed in a magnetic field, gadodiamide generates a large local magnetic field, which can enhance the relaxation rate of nearby protons. This change in proton relaxation dynamics, iincreases the MRI signal intensity of tissues in which gadodiamide has accumulated; therefore, visualization of those tissues is enhanced. |
| Display_Name |
Gadodiamide |
| FDA_UNII_Code |
84F6U3J2R6 |
| FULL_SYN |
Gadodiamide Gadolinium, (5,8-bis((carboxy-kappaO)methyl)-11-(2-(methylamino)-2-(oxo-kappaO)ethyl)-3-(oxo-kappaO)-2,5,8,11-tetraazatridecan-13-oato(3-)-kappaN5,kappaN8,kappaN11,kappaO13)- Gd-DTPA-BMA OmniScan DV 7572 Gadolinium-DTPA-BMA GADODIAMIDE HSDB 7547 |
| label |
Gadodiamide |
| Legacy Concept Name |
Gadodiamide |
| NCI_Drug_Dictionary_ID |
779661 |
| PDQ_Closed_Trial_Search_ID |
779661 |
| PDQ_Open_Trial_Search_ID |
779661 |
| Preferred_Name |
Gadodiamide |
| prefixIRI |
Thesaurus:C65795 |
| prefLabel |
Gadodiamide |
| Semantic_Type |
Organic Chemical Indicator, Reagent, or Diagnostic Aid |
| UMLS_CUI |
C0082646 |
| subClassOf |